Fibroblast Growth Factor Receptor 3 Interacts with and Activates TGF beta-Activated Kinase 1 Tyrosine Phosphorylation and NFkB Signaling in Multiple Myeloma and Bladder Cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081707%3A_____%2F14%3A00440592" target="_blank" >RIV/68081707:_____/14:00440592 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1371/journal.pone.0086470" target="_blank" >http://dx.doi.org/10.1371/journal.pone.0086470</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1371/journal.pone.0086470" target="_blank" >10.1371/journal.pone.0086470</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Fibroblast Growth Factor Receptor 3 Interacts with and Activates TGF beta-Activated Kinase 1 Tyrosine Phosphorylation and NFkB Signaling in Multiple Myeloma and Bladder Cancer

Popis výsledku v původním jazyce

Cancer is a major public health problem worldwide. In the United States alone, 1 in 4 deaths is due to cancer and for 2013 a total of 1,660,290 new cancer cases and 580,350 cancer-related deaths are projected. Comprehensive profiling of multiple cancer genomes has revealed a highly complex genetic landscape in which a large number of altered genes, varying from tumor to tumor, impact core biological pathways and processes. This has implications for therapeutic targeting of signaling networks in the development of treatments for specific cancers. The NF kappa B transcription factor is constitutively active in a number of hematologic and solid tumors, and many signaling pathways implicated in cancer are likely connected to NF kappa B activation. A critical mediator of NF kappa B activity is TGF beta-activated kinase 1 (TAK1). Here, we identify TAK1 as a novel interacting protein and target of fibroblast growth factor receptor 3 (FGFR3) tyrosine kinase activity.

Název v anglickém jazyce

Fibroblast Growth Factor Receptor 3 Interacts with and Activates TGF beta-Activated Kinase 1 Tyrosine Phosphorylation and NFkB Signaling in Multiple Myeloma and Bladder Cancer

Popis výsledku anglicky

Cancer is a major public health problem worldwide. In the United States alone, 1 in 4 deaths is due to cancer and for 2013 a total of 1,660,290 new cancer cases and 580,350 cancer-related deaths are projected. Comprehensive profiling of multiple cancer genomes has revealed a highly complex genetic landscape in which a large number of altered genes, varying from tumor to tumor, impact core biological pathways and processes. This has implications for therapeutic targeting of signaling networks in the development of treatments for specific cancers. The NF kappa B transcription factor is constitutively active in a number of hematologic and solid tumors, and many signaling pathways implicated in cancer are likely connected to NF kappa B activation. A critical mediator of NF kappa B activity is TGF beta-activated kinase 1 (TAK1). Here, we identify TAK1 as a novel interacting protein and target of fibroblast growth factor receptor 3 (FGFR3) tyrosine kinase activity.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

BO - Biofyzika

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

PLoS ONE

ISSN

1932-6203

e-ISSN

—

Svazek periodika

9

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

—

Kód UT WoS článku

000330288000101

EID výsledku v databázi Scopus

—